Development Stage
Program (Target)
Indication
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Program
LM11A-31 (p75NTR)
Indication: Alzheimer's Disease
Phase 2a completed1
Indication: HIV Dementia
Q4 2026
Indication: Rare Neuro Indication
In Evaluation
Program
PTX-4-3 (TrkB)
Indication: Neurodegeneration
Program
PTX-10-3 (TrkB/C)
Indication: Neurodegeneration
Development programs
Select an indication to explore its development stages.
LM11A-31
Target (p75NTR)
Alzheimer's Disease Phase 2a completed1
Development Stage
Progressive Supranuclear Palsy Enrolling
HIV Dementia Q4 2026
Development Stage
Rare Neuro Indication In Evaluation
Development Stage
PTX-4-3
Target (TrkB)
Neurodegeneration View development stages
Development Stage
PTX-10-3
Target (TrkB/C)
Neurodegeneration View development stages
Development Stage
1 Shanks et al. p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial. Nat Med 30, 1761–1770 (2024)
If you are reaching out to PharmatrophiX for information on the CurePSP trial in partnership with UCSF please visit CurePSP or UCSF for additional information.